[1]
Giroulet F, Tabotta F, Pomoni A, Prior J. Primary parotid Merkel cell carcinoma: a first imagery and treatment response assessment by 18F-FDG PET. BMJ case reports. 2019 Mar 9:12(3):. doi: 10.1136/bcr-2018-226511. Epub 2019 Mar 9
[PubMed PMID: 30852509]
Level 3 (low-level) evidence
[2]
Villani A, Fabbrocini G, Costa C, Carmela Annunziata M, Scalvenzi M. Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies. Dermatology and therapy. 2019 Jun:9(2):209-222. doi: 10.1007/s13555-019-0288-z. Epub 2019 Feb 28
[PubMed PMID: 30820877]
[3]
Aung PP, Parra ER, Barua S, Sui D, Ning J, Mino B, Ledesma DA, Curry JL, Nagarajan P, Torres-Cabala CA, Efstathiou E, Hoang AG, Wong MK, Wargo JA, Lazar AJ, Rao A, Prieto VG, Wistuba I, Tetzlaff MT. B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Jun 1:25(11):3455-3467. doi: 10.1158/1078-0432.CCR-18-2355. Epub 2019 Feb 26
[PubMed PMID: 30808776]
[4]
Liu W, Krump NA, Buck CB, You J. Merkel Cell Polyomavirus Infection and Detection. Journal of visualized experiments : JoVE. 2019 Feb 7:(144):. doi: 10.3791/58950. Epub 2019 Feb 7
[PubMed PMID: 30799855]
[5]
Barreira JV, Valejo Coelho MM, Ribeiro C, Semedo M. Unknown primary Merkel cell carcinoma with cutaneous spread. BMJ case reports. 2019 Feb 21:12(2):. doi: 10.1136/bcr-2018-224834. Epub 2019 Feb 21
[PubMed PMID: 30796073]
Level 3 (low-level) evidence
[6]
Baez CF, Gonçalves MTV, da Rocha WM, Magalhães de Souza L, Savassi-Ribas F, de Oliveira Almeida NK, Delbue S, Guimarães MAAM, Cavalcanti SMB, Luz FB, Varella RB. Investigation of three oncogenic epitheliotropic viruses shows human papillomavirus in association with non-melanoma skin cancer. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2019 Jun:38(6):1129-1133. doi: 10.1007/s10096-019-03508-z. Epub 2019 Feb 21
[PubMed PMID: 30788731]
[7]
Uitentuis SE, Louwman MWJ, van Akkooi ACJ, Bekkenk MW. Treatment and survival of Merkel cell carcinoma since 1993: A population-based cohort study in The Netherlands. Journal of the American Academy of Dermatology. 2019 Oct:81(4):977-983. doi: 10.1016/j.jaad.2019.01.042. Epub 2019 Jan 29
[PubMed PMID: 30703452]
[8]
Schwartz JL, Wong SL, McLean SA, Hayman JA, Lao CD, Kozlow JH, Malloy KM, Bradford CR, Frohm ML, Fullen DR, Lowe L, Bichakjian CK. NCCN Guidelines implementation in the multidisciplinary Merkel Cell Carcinoma Program at the University of Michigan. Journal of the National Comprehensive Cancer Network : JNCCN. 2014 Mar 1:12(3):434-41
[PubMed PMID: 24616547]
[9]
Gallo M, Guarnotta V, De Cicco F, Rubino M, Faggiano A, Colao A, NIKE Group. Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. Journal of cancer research and clinical oncology. 2019 Feb:145(2):429-443. doi: 10.1007/s00432-019-02839-w. Epub 2019 Jan 7
[PubMed PMID: 30617553]
[10]
Tétu P, Baroudjian B, Madelaine I, Delyon J, Lebbé C. [Update in treatment for Merkel Cell Carcinoma and clinical practice guide]. Bulletin du cancer. 2019 Jan:106(1):64-72. doi: 10.1016/j.bulcan.2018.11.009. Epub 2018 Dec 19
[PubMed PMID: 30579571]
[11]
Goldstein RH, DeCaprio JA. Merkel Cell Carcinoma in the HIV-1/AIDS Patient. Cancer treatment and research. 2019:177():211-229. doi: 10.1007/978-3-030-03502-0_8. Epub
[PubMed PMID: 30523626]
[12]
Del Marmol V, Lebbé C. New perspectives in Merkel cell carcinoma. Current opinion in oncology. 2019 Mar:31(2):72-83. doi: 10.1097/CCO.0000000000000508. Epub
[PubMed PMID: 30694842]
Level 3 (low-level) evidence
[13]
Perez MC, de Pinho FR, Holstein A, Oliver DE, Naqvi SMH, Kim Y, Messina JL, Burke E, Gonzalez RJ, Sarnaik AA, Cruse CW, Wuthrick EJ, Harrison LB, Sondak VK, Zager JS. Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough? Annals of surgical oncology. 2018 Oct:25(11):3334-3340. doi: 10.1245/s10434-018-6688-y. Epub 2018 Aug 2
[PubMed PMID: 30073600]
[14]
Cook M, Baker K, Redman M, Lachance K, Nguyen MH, Parvathaneni U, Bhatia S, Nghiem P, Tseng YD. Differential Outcomes Among Immunosuppressed Patients With Merkel Cell Carcinoma: Impact of Immunosuppression Type on Cancer-specific and Overall Survival. American journal of clinical oncology. 2019 Jan:42(1):82-88. doi: 10.1097/COC.0000000000000482. Epub
[PubMed PMID: 30211723]
[15]
Dasanu CA, Del Rosario M, Codreanu I, Hyams DM, Plaxe SC. Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors? Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2019 Jan:25(1):214-216. doi: 10.1177/1078155218785002. Epub 2018 Jun 22
[PubMed PMID: 29933728]